Friday, February 10, 2012 Issue 3   VOLUME 1 ISSUE 3   HOME TOPICS Parkinson's disease ARCHIVE Issue 1 April 7, 2004 Vol. 1 Issue 1 [MORE] SEARCH Search for articles containing: SUBSCRIBE Subscribe to WE MOVE News Parkinson's disease The Use of Pergolide May Be Linked to Changes in Heart Valves Previously published reports have identified a limited number of cases of abnormalities in the heart valves of patients who have taken pergolide. In a study that was published in the journal Lancet in April 2004, researchers examined all patients with Parkinson's disease in their clinic and found that the connection between the use of pergolide and damage to heart valves was more common than previously thought to be. [FULL STORY]   Results from a Preliminary Study of the Use of Glial Cell-Line Derived Neurotrophic Factor in Parkinson's Disease Hold Promise In a report presented at the American Academy of Neurology meeting in San Francisco, researchers provided the results of a preliminary study of the treatment of Parkinson's disease with glial cell-line derived neurotrophic factor (GNDF). In this two-year study, the five patients showed improved scores on a subjective rating scale and increased density in dopamine transporters on imaging studies. GDNF is a protein that the body requires in order to create, maintain, and grow nerve cells. [FULL STORY]     Supported by an educational grant from the Medtronic Foundation Published by WE MOVE Copyright © 2004 WE MOVE. All rights reserved. TELL A FRIEND   Judith Blazer, Executive Director, WE MOVE   Meghan Murphy, CME and Communications Coordinator   Edited by Richard Robinson, Cate Murray and Joy Leffler

Powered by IMN™